cholestenoic acid: structure in first source
(25R)-3beta-hydroxycholest-5-en-26-oic acid : A 3beta-hydroxycholest-5-en-26-oic acid in which the stereocentre at position 25 has R-configuration.
ID Source | ID |
---|---|
PubMed CID | 40579073 |
CHEBI ID | 86378 |
SCHEMBL ID | 17413741 |
MeSH ID | M0318338 |
Synonym |
---|
cholestenoic acid |
LMST04030072 , |
3beta-hydroxycholest-5-en-25r-26-oic acid |
hydroxycholestenoic acid |
CHEBI:86378 |
(25r)-3beta-hydroxycholest-5-en-26-oic acid |
SCHEMBL17413741 |
56845-87-5 |
3-hydroxy-5-cholestenoate |
3 beta-hydroxycholest-5-en-27-oate |
3beta-hydroxy-5-cholesten-26-oate |
(3beta)-3-hydroxy-cholest-5-en-26-oate |
(3beta)-3-hydroxy-cholest-5-en-26-oic acid |
3-hydroxy-5-cholesten-26-oate |
3 beta-hydroxycholest-5-en-27-oic acid |
Q27159118 |
(3beta,25r)-3-hydroxycholest-5-en-26-oic acid |
DTXSID701267672 |
CS-0646545 |
5-cholestene-26-oic acid-3|a-ol |
cholest-5-en-26-oic acid, 3-hydroxy-, (3beta,25r)- |
HY-N11299 |
Class | Description |
---|---|
3beta-hydroxycholest-5-en-26-oic acid | A steroid acid resulting from the oxidation of one of the terminal methyl groups of cholesterol to the corresponding aldehyde. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
Oxysterols derived from cholesterol | 38 | 31 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (15.79) | 29.6817 |
2010's | 13 (68.42) | 24.3611 |
2020's | 3 (15.79) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (5.26%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (94.74%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |